AUTHOR=Deblieck Choi , Smeijers Steven , Morlion Bart , Datta Abhishek , Thomas Chris , Theys Tom TITLE=Case Report: Initial Evidence of Safety and Efficacy of High Definition-Transcranial Direct Current Stimulation in a Patient With Neuropathic Pain and Implanted Spinal Cord Stimulator JOURNAL=Frontiers in Pain Research VOLUME=Volume 2 - 2021 YEAR=2021 URL=https://www.frontiersin.org/journals/pain-research/articles/10.3389/fpain.2021.753464 DOI=10.3389/fpain.2021.753464 ISSN=2673-561X ABSTRACT=Neuropathic pain (NP), often treatment-refractory, is one of the most debilitating conditions contributing to suffering and disability worldwide. Recently, non-invasive neuromodulation techniques, particularly repetitive transcranial magnetic stimulation (rTMS) and transcranial direct current stimulation (tDCS) have emerged as potential therapeutic alternatives due to their ability to alter cortical excitability of neural circuits. However, the magnetic field induced in rTMS may be unsafe for patients with an implant in the head or neck area while tDCS poses no theoretical risk of injury to these patients. High definition (HD)-tDCS is a novel, more focal approach and may be safer compared to the more diffused conventional tDCS. In a 54-year-old woman with an SCS system for another pain syndrome, HD-tDCS was initiated for refractory post-surgical inferior alveolar nerve neuropathy. She was submitted to 7 days of anodal HD-tDCS over the left motor cortex at 1.5 mA for 30 min. A notable decrease in pain perception was observed, lasting for approximately five to six hours (Numeric Rating Score decreased from 8 to 4.34). No adverse events were reported. The stimulation parameters and clinical efficacy of the SCS system remained unchanged. Additionally, computational analysis indicated no meaningful alteration of current flow when considering a model with a SCS implant with respect to a model without implant. Regarding the positive therapeutic effect of HD-tDCS, the patient was selected for an epidural motor cortex stimulation (MCS) trial and subsequent implantation, which showed short-term pain relief of 50-75%. Although one case does not demonstrate efficacy, tolerability, or safety of the novel intervention, it paves the way for better diagnosis and treatment for patients who are otherwise excluded from other options, such as rTMS. A positive tDCS effect could be a potential biomarker for positive epidural MCS response in patients with an implanted stimulation device non-compatible with rTMS. To our knowledge, this is the first use of HD-tDCS as predictive tool for a positive response in chronic epidural MCS, especially in patients with an implanted device not suitable for rTMS. Furthermore, our simulation results help substantiate use of HD-tDCS in patients with SCS, for the first time.